Exploratory Clinical Study on Controlled álak Microdosing for Post-Detoxification Recovery
DOI:
Abstract
Post-detoxification phases of methamphetamine dependence are often characterized by neurophysiological instability, including tremors, insomnia, and anxiety, due to suppressed GABAergic activity and hyperdopaminergic rebound. Traditional Filipino distilled spirit, álak or lambanog, contains trace levels of ethanol and minor fusel alcohols which may exert mild GABA-A receptor agonism when microdosed under medical supervision. This exploratory clinical study investigates the potential of controlled álak microdosing as an adjunct for stabilizing central nervous system function in post-detoxified methamphetamine patients. Twelve post-detoxification patients (n=12) from rehabilitation centers in Quezon and Batangas were administered álak microdoses (≤10% ethanol, 5–10 ml/day) for 14 days under medical supervision. Physiological and psychological parameters including sleep quality, tremor frequency, and anxiety, were measured using the Clinical Opiate Withdrawal Scale (COWS) adapted for stimulant recovery and the Beck Anxiety Inventory (BAI). Data were analyzed descriptively and statistically using paired t-tests. Eight out of twelve participants (66.7%) demonstrated marked improvement in sleep continuity (p<0.05), tremor reduction (p<0.05), and decreased anxiety scores (mean reduction 23.4%, p<0.05). No signs of ethanol intoxication, craving substitution, or hepatic distress were observed. Mild headache was reported in one participant but resolved spontaneously. Controlled álak microdosing exhibits promising GABAergic modulatory effects that may facilitate neurophysiological stabilization in methamphetamine recovery. While preliminary, these findings support further biochemical validation and integration of ethnopharmacological knowledge into harm-reduction frameworks.
Downloads
Views : 120
Downloads : 128
References
F. Besana, S. Pasquariello, A. Negri, and V. Costa, “Crystal Meth’ Use in an Addiction Outpatient Clinic in Italy: A Multifaceted Challenge,” Psychoactives, vol. 4, no. 3, p. 25, 2025.
N. Simbulan, L. Estacio, C. Dioquino-Maligaso, T. Herbosa, and M. Withers, “The Manila Declaration on the Drug Problem in the Philippines,” Annals of Global Health, vol. 85, no. 1, p. 26, Mar. 2019.
J. R. Yates, “Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets,” Substance Abuse and Rehabilitation, vol. 15, pp. 125–161, Aug. 2024.
R. N. Dharavath et al., “GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential,” Frontiers in Neural Circuits, vol. 17, p. 1218737, Oct. 2023.
M. Perovic, D. Pavlovic, Z. Palmer, M. S. B. Udo, C. T. Citadin, K. M. Rodgers, C. Y.-C. Wu, Q. Zhang, H. W. Lin, and V. Tesic, “Modulation of GABAergic system as a therapeutic option in stroke,” Experimental Neurology, vol. 384, p. 115050, Feb. 2025.
L. Lu, S. Ni, X. He, Y. Huang, X. Chen, and Z. Yang, “From tradition to evidence-base: Leveraging TCM human use experience in modern drug development,” Pharmacological Research - Modern Chinese Medicine, vol. 13, p. 100535, Dec. 2024.
A. B. Martinez, M. Co, J. Lau, and J. S. L. Brown, “Filipino help-seeking for mental health problems and associated barriers and facilitators: a systematic review,” Social Psychiatry and Psychiatric Epidemiology, vol. 55, no. 11, pp. 1397–1413, Nov. 2020.
Z. Huang, J. Miao, J. Chen, Y. Zhong, S. Yang, Y. Ma, and C. Wen, “A traditional Chinese medicine syndrome classification model based on cross-feature generation by convolution neural network: model development and validation,” JMIR Medical Informatics, vol. 10, no. 4, 2022.
J. A. Jones, K. Zuhlsdorff, and J. W. Dalley, “Neurochemical substrates linked to impulsive and compulsive phenotypes in addiction: A preclinical perspective,” Journal of Neurochemistry, vol. 157, no. 5, pp. 1525–1546, 2021.
H. G. Warlick, G. N. De Souza, and V. S. Gallicchio, “Restoration of GABAA receptor function after benzodiazepine use: A meta-analysis,” Journal of Stem Cell Research, vol. 1, no. 1, pp. 1–19, 2020.
A. N. Edinoff, C. A. Nix, J. Hollier, C. E. Sagrera, B. M. Delacroix, T. Abubakar, E. M. Cornett, A. M. Kaye, and A. D. Kaye, “Benzodiazepines: Uses, dangers, and clinical considerations,” Neurology International, vol. 13, no. 4, pp. 594–607, 2021.
H. Mashayekhi-Sardoo, F. Razazpour, Z. Hakemi, et al., “Ethanol-induced depression: Exploring the underlying molecular mechanisms,” Cellular and Molecular Neurobiology, vol. 45, 2025.
P. F. S. Mendes, D. C. Baia-da-Silva, W. W. P. Melo, L. O. Bittencourt, R. D. Souza-Rodrigues, L. M. P. Fernandes, C. D. S. F. Maia, and R. R. Lima, “Neurotoxicology of alcohol: A bibliometric and science mapping analysis,” Frontiers in Pharmacology, vol. 14, Aug. 2023.
S. Pallanti, J. Zohar, S. Kasper, H.-J. Möller, and E. Hollander, “Revisiting benzodiazepines (GABA enhancers): A transdiagnostic and precision medicine approach,” Journal of Psychiatric Research, vol. 170, pp. 65–72, Feb. 2024.
K. Shakeri-Nejad, A. Gardin, C. Gray, S. Neelakantham, S. Dumitras, and E. Legangneux, “Safety, tolerability, pharmacodynamics and pharmacokinetics of intravenous siponimod: A randomized, open-label study in healthy subjects,” Clinical Pharmacology in Drug Development, vol. 42, no. 1, pp. 175–195, Jan. 2020.
B. T. Thomas, Anti-oxidant and Anti-microbial Activities of Flavonoids from the Fruit Extract of Dacryodes edulis, Olabisi Onabanjo University, Jan. 2021.
V. Arzani, M. Soleimani, T. Fritsch, U. M. Jacob, V. Calabrese, and A. Arzani, “Plant polyphenols, terpenes, and terpenoids in oral health,” Open Medicine (Warsaw), vol. 20, no. 1, 2025.
The Official Abstract Book of Juvenes Pro Medicina 2024 Conference, Students’ Scientific Association of the Medical University of Lodz, Łódź, Poland, 2024.
N. A. O. Rondilla, I. C. N. Rocha, S. J. R. Roque, R. M. S. Lu, N. L. B. Apolinar, A. A. Solaiman-Balt, T. J. J. Abion, P. B. P. Banatin, and C. V. M. Javier, “Folk Medicine in the Philippines: A Phenomenological Study of Health-Seeking Individuals,” International Journal of Medical Students, Apr. 29, 2021.
N. Abbaspour, “Fermentation's pivotal role in shaping the future of plant-based foods: An integrative review of fermentation processes and their impact on sensory and health benefits,” Applied Food Research, vol. 4, no. 2, Art. no. 100468, Dec. 2024.
N. K. Leeuwendaal, C. Stanton, P. W. O'Toole, and T. P. Beresford, “Fermented foods, health and the gut microbiome,” Nutrients, vol. 14, no. 7, Art. no. 1527, Apr. 2022.
A. Bo, T. C. Goings, C. B. R. Evans, A. Sharma, Z. Jennings, B. Durand, A. Bardeen, and A. Murray-Lichtman, “Culturally sensitive prevention programs for substance use among adolescents of color: A systematic review and meta-analysis of randomized controlled trials,” Clin. Psychol. Rev., vol. 99, Art. no. 102233, Feb. 2023.
W. Asare-Doku, S. Settumba Stolk, A. Peacock, A. Shakeshaft, E. Waller, S. Nathan, A. Craig, G. Economidis, J. Ravulo, et.al, Monitoring and Evaluation of the Kava Pilot Program: Final Report, National Drug and Alcohol Research Centre, UNSW, Nov. 2023.
M. van Elk, G. Fejer, P. Lempe, L. Prochazckova, M. Kuchar, K. Hajkova, and J. Marschall, “Effects of psilocybin microdosing on awe and aesthetic experiences: A preregistered field and lab-based study,” Psychopharmacology (Berl.), vol. 239, no. 6, pp. 1705–1720, Jun. 2022.
K. C. Tanalgo, Y. Plang, K. C. Dela Cruz, et. al, “Diversity and ecological factors influencing medicinal plant use among ethnolinguistic groups in the Philippines,” Integr. Conserv., vol. 4, no. 2, pp. 231–245, Apr. 2025.
N. A. O. Rondilla, I. C. N. Rocha, S. J. R. Roque, R. M. S. Lu, N. L. B. Apolinar, A. A. Solaiman-Balt, T. J. J. Abion, P. B. P. Banatin, and C. V. M. Javier, “Folk medicine in the Philippines: A phenomenological study of health-seeking individuals,” Int. J. Med. Stud., vol. 9, no. 1, pp. 25–32, 2021.
A. J. LaHood and S. J. Kok, “Ethanol toxicity,” in StatPearls. Treasure Island, FL: StatPearls Publishing, Jan. 2025.
C. A. Marks, K. Trought, S. Brown, J. Arrow, and B. Hopkins, “Sensitivity of high conservation value birds to para-aminopropiophenone (PAPP) determined by sub-lethal dose–response assay,” Animals, vol. 13, no. 3, 2023.
D. Pati, L. R. Taxier, M. Xia, S. I. Lee, S. Y. Conley, T. Sides, K. M. Boyt, A. C. Hunker, L. S. Zweifel, and T. L. Kash, “Dopamine D2 receptors in the bed nucleus of the stria terminalis modulate alcohol-related behaviors,” Addict. Neurosci., vol. 11, Art. no. 100157, Jun. 2024.
R. A. Hendler, V. A. Ramchandani, J. M. Gilman, and D. W. Hommer, “Stimulant and sedative effects of alcohol,” Curr. Top. Behav. Neurosci., vol. 13, pp. 489–509, May 2011.
D. Leelavanich, N. Adjimatera, L. Broese Van Groenou, and P. Anantachoti, “Prescription and non-prescription drug classification systems across countries: Lessons learned for Thailand,” Risk Manag. Healthc. Policy, vol. 13, pp. 2753–2768, Nov. 2020.
H. Gjerde, M. A. Huestis, G. Mulima, C. Kajombo, M. Sundet, and F. Pechansky, “Recommendations for effective collaboration and capacity building in epidemiological studies on the effect of alcohol and drug use on traffic safety in low- and middle-income countries,” Traffic Inj. Prev., vol. 25, no. 3, pp. 313–321, 2024.
C. Corley, A. Craig, S. Sadek, J. A. Marusich, S. N. Chehimi, A. M. White, L. J. Holdiness, B. C. Reiner, and C. D. Gipson, “Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment options,” Pharmacol. Biochem. Behav., vol. 243, Art. no. 173836, Oct. 2024.
J. R. Melchior, R. E. Perez, G. J. Salimando, J. R. Luchsinger, A. Basu, and D. G. Winder, “Cocaine augments dopamine mediated inhibition of neuronal activity in the dorsal bed nucleus of the stria terminalis,” J. Neurosci., 2021.
D. W. Bloodgood, J. A. Hardaway, C. M. Stanhope, D. Pati, M. M. Pina, S. Neira, S. Desai, K. M. Boyt, R. D. Palmiter, and T. L. Kash, “Kappa opioid receptor and dynorphin signaling in the central amygdala regulates alcohol intake,” Mol. Psychiatry, 2020.
